Development Status
A multicenter Phase 1 dose escalation trial of PX-866 in patients with advanced metastatic cancer is in progress. This study is being conducted to determine the maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle. The trial is also designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of PX-866.
For information on PX-866 clinical trials, please visit the PX-866 Phase 1 trial description posted on ClinicalTrials.gov.
|
